Third Pole Therapeutics Triumphs with eNOfit™ System EFS for Non-Hospital Treatment of Pulmonary Hypertension
Overview
- Company: Third Pole Therapeutics
- Indication: Pulmonary hypertension associated with Interstitial Lung Disease (ILD)
- Drug: eNOfit™ (Inhaled Nitric Oxide Delivery System)
- Trial Phase: N/A
- NCT ID: Not available
Early Feasibility Study (EFS) Success
Third Pole Therapeutics, a forefront enterprise in developing therapeutic solutions for cardiopulmonary and infectious diseases, has recently achieved success with an Early Feasibility Study (EFS) under an FDA-approved Investigational Device Exemption. The company's innovative eNOfit™ system is a state-of-the-art, compact, portable inhaled nitric oxide (iNO) generator and delivery platform tailored for out-of-hospital treatment of patients with pulmonary hypertension, a condition often linked to Interstitial Lung Disease (ILD).
The positive results from the EFS confirm the safety and functionality of the eNOfit™ system. This paves the way for Third Pole Therapeutics to undertake larger-scale randomized, placebo-controlled trials aimed at establishing the safety and efficacy of the system. The company's goal is to demonstrate that the benefits of iNO therapy, traditionally limited to in-hospital use for pulmonary hypertension management, can be extended to non-hospital environments, potentially improving the lives of patients affected by chronic respiratory diseases such as ILD and COPD.
Innovation and Funding
Under the leadership of Dr. Warren Zapol, Third Pole Therapeutics has pioneered the industry with its patented technology capable of on-demand generation and delivery of NO for inhalation, thereby eliminating the risks and logistical challenges associated with traditional compressed gas cylinders.
The company offers groundbreaking platforms, including eNOfit™ and eNOcare™, which exemplify a practical 'make it and take it' therapeutic approach. Third Pole's advancements could revolutionize the treatment strategies for a wide array of conditions, including ILD, COPD, cystic fibrosis, heart failure, and several critical infectious diseases.
The impactful research and development initiatives at Third Pole Therapeutics have been supported by grants from prestigious institutions such as the National Heart, Lung, and Blood Institute and the National Center for Advancing Translational Sciences.